SG11201906313SA - A polypeptide linker for preparing multispecific antibodies - Google Patents

A polypeptide linker for preparing multispecific antibodies

Info

Publication number
SG11201906313SA
SG11201906313SA SG11201906313SA SG11201906313SA SG11201906313SA SG 11201906313S A SG11201906313S A SG 11201906313SA SG 11201906313S A SG11201906313S A SG 11201906313SA SG 11201906313S A SG11201906313S A SG 11201906313SA SG 11201906313S A SG11201906313S A SG 11201906313SA
Authority
SG
Singapore
Prior art keywords
international
multispecific antibodies
paris
pct
polypeptide linker
Prior art date
Application number
SG11201906313SA
Other languages
English (en)
Inventor
Eugene Zhukovsky
Olivier Leger
Original Assignee
Biomunex Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomunex Pharmaceuticals filed Critical Biomunex Pharmaceuticals
Publication of SG11201906313SA publication Critical patent/SG11201906313SA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SG11201906313SA 2017-01-09 2018-01-09 A polypeptide linker for preparing multispecific antibodies SG11201906313SA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17305022 2017-01-09
PCT/EP2018/050481 WO2018127608A1 (en) 2017-01-09 2018-01-09 A polypeptide linker for preparing multispecific antibodies

Publications (1)

Publication Number Publication Date
SG11201906313SA true SG11201906313SA (en) 2019-08-27

Family

ID=57984856

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201906313SA SG11201906313SA (en) 2017-01-09 2018-01-09 A polypeptide linker for preparing multispecific antibodies

Country Status (13)

Country Link
US (1) US11958913B2 (ko)
EP (1) EP3565847A1 (ko)
JP (2) JP2020503873A (ko)
KR (1) KR102589422B1 (ko)
CN (1) CN110520444A (ko)
AU (1) AU2018206229A1 (ko)
BR (1) BR112019014147A2 (ko)
CA (1) CA3052084A1 (ko)
IL (1) IL267886A (ko)
MX (1) MX2019008241A (ko)
SG (1) SG11201906313SA (ko)
WO (1) WO2018127608A1 (ko)
ZA (1) ZA201905160B (ko)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102361412B1 (ko) 2016-03-25 2022-02-09 바이오뮤넥스 파마슈티컬스 Cd38 및 pd-l1에 대한 결합 분자
CN110520444A (zh) * 2017-01-09 2019-11-29 拜奥穆尼克斯制药 用于制备多特异性抗体的多肽接头
AU2018241881A1 (en) 2017-03-27 2019-11-07 Biomunex Pharmaceuticals Stable multispecific antibodies
JP2022515424A (ja) 2018-12-24 2022-02-18 サノフイ 突然変異ｆａｂドメインを有する多重特異性結合タンパク質
CN115724986A (zh) * 2022-07-11 2023-03-03 惠和生物技术(上海)有限公司 三特异性抗体及其用途

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2857516T3 (en) * 2000-04-11 2017-08-07 Genentech Inc Multivalent antibodies and uses thereof
EP1549345A1 (en) * 2002-10-10 2005-07-06 MERCK PATENT GmbH Bispecific anti-erb-b antibodies and their use in tumor therapy
US7910101B2 (en) * 2004-10-25 2011-03-22 Centocor, Inc. Melanocortin receptor binding mimetibodies, compositions, methods and uses
RU2509085C2 (ru) * 2008-01-28 2014-03-10 Медиммун Лимитед Стабилизированные антитела против ангиопоэтина-2 и их применение
WO2012088461A2 (en) 2010-12-23 2012-06-28 Biogen Idec Inc. Linker peptides and polypeptides comprising same
EP2543680A1 (en) 2011-07-07 2013-01-09 Centre National de la Recherche Scientifique Multispecific mutated antibody Fab fragments
CA2851667A1 (en) * 2011-10-11 2013-04-18 Medimmune, Llc Cd40l-specific tn3-derived scaffolds and methods of use thereof
WO2014063704A2 (en) * 2012-10-23 2014-05-01 Statens Serum Institut M. tuberculosis vaccines
DE102014213460B4 (de) * 2014-07-10 2022-10-20 Bayerische Motoren Werke Aktiengesellschaft Klappenanordnung für ein Kraftfahrzeug
GB201500319D0 (en) * 2015-01-09 2015-02-25 Agency Science Tech & Res Anti-PD-L1 antibodies
DK3313441T3 (da) * 2015-06-24 2024-04-15 Janssen Biotech Inc Immunmodulering og behandling af faste tumorer med antistoffer, der specifikt binder cd38
KR102361412B1 (ko) * 2016-03-25 2022-02-09 바이오뮤넥스 파마슈티컬스 Cd38 및 pd-l1에 대한 결합 분자
JP7258556B2 (ja) 2016-04-28 2023-04-17 ビオミューネクス・ファルマシューティカル Ｅｇｆｒ及びｈｅｒ２をターゲティングする二重特異性抗体
CN110520444A (zh) * 2017-01-09 2019-11-29 拜奥穆尼克斯制药 用于制备多特异性抗体的多肽接头
AU2018241881A1 (en) 2017-03-27 2019-11-07 Biomunex Pharmaceuticals Stable multispecific antibodies

Also Published As

Publication number Publication date
WO2018127608A1 (en) 2018-07-12
KR102589422B1 (ko) 2023-10-13
ZA201905160B (en) 2021-05-26
US20190330377A1 (en) 2019-10-31
JP2023027215A (ja) 2023-03-01
US11958913B2 (en) 2024-04-16
JP2020503873A (ja) 2020-02-06
IL267886A (en) 2019-09-26
MX2019008241A (es) 2019-12-09
RU2019125228A3 (ko) 2021-04-22
EP3565847A1 (en) 2019-11-13
CA3052084A1 (en) 2018-07-12
AU2018206229A1 (en) 2019-08-29
RU2019125228A (ru) 2021-02-09
BR112019014147A2 (pt) 2020-02-11
CN110520444A (zh) 2019-11-29
KR20190102271A (ko) 2019-09-03

Similar Documents

Publication Publication Date Title
SG11201906313SA (en) A polypeptide linker for preparing multispecific antibodies
SG11201903857UA (en) Antibodies to pd-1 and uses thereof
SG11201909949XA (en) Targeted immunotolerance
SG11201809064QA (en) Chimeric neurotoxins
SG11201910019PA (en) Microorganisms and methods for producing cannabinoids and cannabinoid derivatives
SG11201810933QA (en) Anti-c5 antibodies and uses thereof
SG11201906763RA (en) Pyrrolo [1,2-b] pyridazine derivatives
SG11201907673YA (en) Pharmaceutical compositions for combination therapy
SG11201810149VA (en) Anti hla-g specific antibodies
SG11201807827VA (en) Process for the preparation of pegylated drug-linkers and intermediates thereof
SG11201809499UA (en) Processes for preparing phosphorodiamidate morpholino oligomers
SG11201908325PA (en) Process for the preparation of glucuronide drug-linkers and intermediates thereof
SG11201808710UA (en) Novel immunogenic cd1d binding peptides
SG11201907434RA (en) Compositions and methods for immunooncology
SG11201808222RA (en) Methods of treatment of cholestatic diseases
SG11201903287PA (en) Anti-respiratory syncytial virus antibodies, and methods of their generation and use
SG11201810965YA (en) 1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors
SG11201809497RA (en) Processes for preparing phosphorodiamidate morpholino oligomers
SG11201906041QA (en) Pharmaceutical compositions for combination therapy
SG11201908825TA (en) Stable multispecific antibodies
SG11201909680UA (en) Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds
SG11201909807TA (en) Methods of manufacturing of niraparib
SG11201804704PA (en) Compositions and methods for decreasing tau expression
SG11201907208XA (en) Radiolabeled anti-lag3 antibodies for immuno-pet imaging
SG11201807062RA (en) Anti-tnfalpha-antibodies and functional fragments thereof